Investor Presentaiton

We strategically started with CRC as the first indication for Shield GUARDANT™ INVESTOR 20 DAY 23 2 Demonstrated high performance in detecting early- stage cancer 1 shield™ Established reimbursement pathway Positive unit economics to scale 4 CRC Clear patient preference for blood 3 101

View entire presentation